Citations

Mayo Clinic

Showing 10 of 108551 citations.

Finding diamonds in the rough: evaluating the quality of meta-analyses in chronic pain – an infographic
Hussain, Nasir , D’Souza, Ryan S. , D'Souza, Ryan S

Regional Anesthesia & Pain Medicine | March 19, 2024 | Volume: 50 | Issue: 5 | Pages: 437-438

10.1136/rapm-2024-105447 | PMID 38508590 Get It

Bevacizumab‐induced pulmonary cystic disease
McNierney, Dakota , Owda, Fahed , Salim, Hamza , Mallah, Shatha M. A., Azar, Jehad , Salim, Hamza , Mallah, Shatha

Respirology Case Reports | March 19, 2024 | Volume: 12 | Issue: 3 | Pages: No page available

10.1002/rcr2.1321 | PMID 38504770 Get It

AbstractThe use of Bevacizumab has significantly advanced the treatment of various malignancies. Bevacizumab's inhibition of angiogenesis is a known mechanism that impedes tumour growth and facilitates chemotherapy delivery; however, its association with the development of cystic lung disease is not fully understood. We report a unique case of a 73‐year‐old woman with a past medical history of metastatic endometrial adenocarcinoma status post‐chemotherapy with bevacizumab that presented with worsening respiratory symptoms. A follow‐up chest CT scan post chemotherapy showed the transformation of the metastatic lesions into cystic formations. After further extensive evaluation, she was diagnosed with pulmonary cystic disease secondary to bevacizumab. This case illustrates a rare presentation of secondary pulmonary cystic disease following Bevacizumab therapy in a patient with metastatic endometrial adenocarcinoma. It highlights the importance of recognizing uncommon side effects of targeted immunotherapy and underscores the need for ongoing research to understand the underlying mechanisms and manage such complications effectively.
European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency
Beuschlein, Felix , Else, Tobias , Hamidi, Oksana , Hulsteijn, Leonie T. van , Karavitaki, Niki , Prete, Alessandro , Vaidya, Anand , Yedinak, Christine, Bancos, Irina , Hamidi, Oksana , van Hulsteijn, Leonie , Karavitaki, Niki , Prete, Alessandro , Vaidya, Anand , Dekkers, Olaf M , Beuschlein, Felix , Bancos, Irina , Hahner, Stefanie , Husebye, Eystein Sverre , Dekkers, Olaf M.

European Journal of Endocrinology | March 19, 2024 | Volume: 190 | Issue: 5 | Pages: G25-G51

10.1093/ejendo/lvae029 | PMID 38714321 Get It

Abstract Glucocorticoids are widely prescribed as anti-inflammatory and immunosuppressive agents. This results in at least 1% of the population using chronic glucocorticoid therapy, being at risk for glucocorticoid-induced adrenal insufficiency. This risk is dependent on the dose, duration and potency of the glucocorticoid, route of administration, and individual susceptibility. Once glucocorticoid-induced adrenal insufficiency develops or is suspected, it necessitates careful education and management of affected patients. Tapering glucocorticoids can be challenging when symptoms of glucocorticoid withdrawal develop, which overlap with those of adrenal insufficiency. In general, tapering of glucocorticoids can be more rapidly within a supraphysiological range, followed by a slower taper when on physiological glucocorticoid dosing. The degree and persistence of HPA axis suppression after cessation of glucocorticoid therapy are dependent on overall exposure and recovery of adrenal function varies greatly amongst individuals. This first European Society of Endocrinology/Endocrine Society joint clinical practice guideline provides guidance on this clinically relevant condition to aid clinicians involved in the care of patients on chronic glucocorticoid therapy.
Antibiotic Prophylaxis in Patients on Extracorporeal Membrane Oxygenation: A Systematic Review
Shah, Sangam , Kashyap, Ashutosh , KC, Anil, Wosti, Deepa, Sanghavi, Devang , Chaudhary, Sanjay, Kar, Biswajit , Shah, Sangam , Chaudhary, Sanjay , Sah, Ranjit , Subedi, Prativa , Bhattacharyya, Anirban, Guru, Pramod

ASAIO Journal | March 19, 2024 | Volume: 70 | Issue: 8 | Pages: e103-e107

10.1097/mat.0000000000002192 | PMID 38502730 Get It

Despite the frequent use of prophylactic antibiotics in hospitals for extracorporeal membrane oxygenation (ECMO) patients, the Extracorporeal Life Support Organization (ELSO) Infectious Disease Task Force does not recommend routine antibiotic prophylaxis due to a lack of compelling evidence. We assessed the effectiveness of prophylactic antibiotics in ECMO patients. We conducted a comprehensive search of multiple databases from their inception up to September 6, 2023, on various databases using keywords like “antibiotics,” “prophylaxis,” “extracorporeal membrane oxygenation,” and “ECMO.” Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included research. We collected data using Microsoft Excel version 2016, mean and standard deviations were calculated for continuous data, while frequencies and percentages were calculated for binomial data. A total of three studies was included in the review with a total of 8,954 participants, of which 4,483 (50.06%) received antibiotic prophylaxis, and 1,131 (25.22%) were female. The administration of antibiotics prophylactically was associated with reduction in rate of mortality, the risk of infections, and complications like acute kidney injury and diarrhea. Although there have been some benefits on antibiotic prophylaxis, prospective research, and possibly the creation of tailored, ECMO-specific bundles will be needed to identify efficient ways to prevent ECMO infection.
Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial
Decar, Spencer G. Van, Carpenter, Elizabeth L. , Vreeland, Timothy J. , Valdera, Franklin A., Tiwari, Ankur, Hale, Diane F. , Hickerson, Annelies T. , Cindass, Jessica L., Hyngstrom, John , Berger, Adam C. , Shaheen, Montaser , Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B. , Peoples, George E. , Decar, Spencer Van , Adams, Alexandra M. , Chick, Robert C. , Clifton, Guy T. , Stojadinovic, Alexander , O’Shea, Anne E. , McCarthy, Patrick M. , Bohan, Phillip M. Kemp , Jakub, James W. , Sussman, Jonathan

No container title available | March 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4088449/v1 Get It

Abstract Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease recurrence in resected Stage III/IV melanoma patients in a Phase IIb trial. The TL particle only (TLPO) vaccine is produced by loading of yeast cell wall particles with autologous TL and direct injection allowing for in vivo DC loading. We have compared the TLPO and TLPLDC vaccines in an embedded Phase I/IIa trial of a larger Phase IIb trial of the TLPLDC vaccine. Methods: Patients rendered clinically disease-free after surgery were randomized 2:1 to receive the TLPO or TLPLDC vaccine and followed for recurrence and death. Patients had scheduled intradermal inoculations at 0, 1, 2, 6, 12, and 18 months after enrollment. Kaplan-Meier and log-rank analysis were used to compare disease-free survival (DFS) and overall survival (OS) in an intention-to-treat (ITT) analysis. Results: Sixty-three patients were randomized, 43 TLPO and 20 TLPLDC. Patients randomized to the TLPO arm were more likely to be female (37.2% vs. 10.0%, p = 0.026), but otherwise no significant clinicopathological differences were identified. No differences in related adverse events (AE) were found between treatment arms. At a median follow-up of 20.5 months, the DFS (60.8% vs. 58.7%, p = 0.714) and OS (94.6% vs. 93.8%, p = 0.966) were equivalent between the TLPO and TLPLDC groups, respectively. No statistical differences were found in subgroup analyses between vaccine types, which accounted for receipt of immunotherapy and the use of G-CSF pre-blood draw. Conclusions: In a randomized, double-blind Phase I/IIa trial, there were no differences in DFS or OS in resected Stage III/IV melanoma patients receiving adjuvant TLPO versus TLPLDC vaccines. Given manufacturing advantages, further efficacy testing of TLPO is warranted in a Phase III trial. Trial Registration This is a clinical trial registered under NCT02301611.
SOCS domain targets ECM assembly in lung fibroblasts and experimental lung fibrosis
Magdaleno, Carina, Tschumperlin, Daniel J. , Varadaraj, Archana

No container title available | March 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4014561/v1 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal disease defined by a progressive decline in lung function due to scarring and accumulation of extracellular matrix (ECM) proteins. The SOCS (Suppressor Of Cytokine Signaling) domain is a 40 amino acid conserved domain known to form a functional ubiquitin ligase complex targeting the Von Hippel Lindau (VHL) protein for proteasomal degradation. Here we show that the SOCS conserved domain operates as a molecular tool, to disrupt collagen and fibronectin fibrils in the ECM associated with fibrotic lung myofibroblasts. Our results demonstrate that fibroblasts differentiated using TGFß, followed by transduction with the SOCS domain, exhibit significantly reduced levels of the contractile myofibroblast-marker, α-SMA. Furthermore, in support of its role to retard differentiation, we find that lung fibroblasts expressing the SOCS domain present with significantly reduced levels of α-SMA and fibrillar fibronectin after differentiation with TGFß. We show that adenoviral delivery of the SOCS domain in the fibrotic phase of experimental lung fibrosis in mice, significantly reduces collagen accumulation in disease lungs. These data underscore a novel function for the SOCS domain and its potential in ameliorating pathologic matrix deposition in lung fibroblasts and experimental lung fibrosis.
Photon-counting CT in Thoracic Imaging: Early Clinical Evidence and Incorporation Into Clinical Practice
Fletcher, Joel G. , Bratt, Alex , Horst, Kelly K. , Koo, Chi Wan , Baffour, Francis , Ko, Jane P. , Rémy‐Jardin, Martine , McCollough, Cynthia H. , Yu, Lifeng , Bratt, Alex , Horst, Kelly , Koo, Chi Wan , Rajiah, Prabhakar Shantha, Baffour, Francis I , Remy-Jardin, Martine , McCollough, Cynthia H , Yu, Lifeng , Fletcher, Joel G , Inoue, Akitoshi , Rajiah, Prabhakar

Radiology | March 19, 2024 | Volume: 310 | Issue: 3 | Pages: No page available

10.1148/radiol.231986 | PMID 38501953 Get It

Variable Energy and Ultrasound–based Liposculpture of the Arms: Multicenter and Multidevice Study
Uribe, Laura C. Cala, Babaitis, Ricardo, Ferrero, Andreina Zannin, Diaz, Manuel F. Aljure, Perez, Mauricio E.

Plastic and Reconstructive Surgery - Global Open | March 19, 2024 | Volume: 12 | Issue: 3 | Pages: e5649

10.1097/gox.0000000000005649 | PMID 38948160 Get It

Summary: Incorporation of new technologies to assist the liposuction procedure is becoming increasingly common. These technologies allow for a softer technique, balanced shaping, elimination of excess adipose tissue, and skin tightening. Some of these technologies include ultrasound (US; US-assisted liposculpture, VASER-assisted liposuction), power suction (power-assisted liposuction), radiofrequency (RF; RF-assisted lipolysis), and laser (laser-assisted liposuction). In addition, some of these devices have been shown to reduce the incidence of hematomas/inflammation and shorten recovery time. We report our experience in high-definition liposculpture of the arms in addition to new technologies to improve skin retraction, comparing their results in terms of complications, satisfaction score, and aesthetic outcomes. We included patients with mild-to-moderate arm dermatochalasis (Duncan classification) fat deposits in the upper extremities who were considered candidates for third-generation US-assisted liposculpture, power-assisted liposuction, RF-assisted lipolysis/skin tightening, and laser-assisted liposuction. A total of 683 consecutive patients met the inclusion criteria for the study. Most of them were women (n = 605, 88%). Fat grafting was performed in 80 patients (11.7%). A significant portion of the patients were secondary cases (n = 223, 33%). Age ranged from 18 to 70 years (median = 38 years). BMI ranged from 17.8 to 34.8 kg/m2 (mean = 24.3 kg/m2). RF-assisted and laser-assisted high-definition liposculpture of the arms are both effective and reproducible techniques for patients who seek an athletic and slim arm contour. A low rate of complications and high satisfaction index support our findings.
Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease
Xie, Zhihui, Desai, Abhishek , Paul, Subrata , Lack, Justin , Scott, Linda A., Eisch, A. Robin, Parikh, Samir M. , Druey, Kirk M. , Ablooglu, Ararat J. , Chen, Wei‐Sheng , Paul, Subrata, Dudek, Arkadiusz Z.

Journal of Clinical Investigation | March 19, 2024 | Volume: 134 | Issue: 10 | Pages: No page available

10.1172/jci169137 | PMID 38502192 Get It

Clarkson disease, or monoclonal gammopathy–associated idiopathic systemic capillary leak syndrome (ISCLS), is a rare, relapsing-remitting disorder featuring the abrupt extravasation of fluids and proteins into peripheral tissues, which in turn leads to hypotensive shock, severe hemoconcentration, and hypoalbuminemia. The specific leakage factor(s) and pathways in ISCLS are unknown, and there is no effective treatment for acute flares. Here, we characterize an autonomous vascular endothelial defect in ISCLS that was recapitulated in patient-derived endothelial cells (ECs) in culture and in a mouse model of disease. ISCLS-derived ECs were functionally hyperresponsive to permeability-inducing factors like VEGF and histamine, in part due to increased endothelial nitric oxide synthase (eNOS) activity. eNOS blockade by administration of N (γ)-nitro-l-arginine methyl ester (l-NAME) ameliorated vascular leakage in an SJL/J mouse model of ISCLS induced by histamine or VEGF challenge. eNOS mislocalization and decreased protein phosphatase 2A (PP2A) expression may contribute to eNOS hyperactivation in ISCLS-derived ECs. Our findings provide mechanistic insights into microvascular barrier dysfunction in ISCLS and highlight a potential therapeutic approach.